This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

Genzyme Corp. and Integrated Genetics, which both launched themselves in 1981, became one in 1989, and since then Genzyme has used IG’s 51 New York Ave. location in Framingham to keep expanding.

PARIS/BOSTON (Reuters) - Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially ...

NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

CAMBRIDGE, Mass. & CARLSBAD, Calif.-Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the Committee for Medicinal Products for ...

FRANKFURT (Reuters) - Genzyme agreed to buy key rights to the leukemia drug Campath, also tested as a multiple sclerosis (MS) treatment, from its German development partner Bayer, the two companies ...

About 18,000 gel-filled syringes sold by the Cambridge biotech Sanofi Genzyme to treat arthritis of the knee should not be used because that batch was linked to a surge in side effects, the company ...

CAMBRIDGE, Mass. – Genzyme Corp. (Nasdaq: GENZ) today announced that it has established a program to participate in efforts to discover and advance novel treatments for neglected diseases affecting ...

Dana Alexander, program director for Genzyme, shows off the company's new $170 million manufacturing facility in Framingham during a tour of the site on Tuesday. BRANDON BUTLER While Cambridge-based ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme Corporation (Nasdaq: GENZ) announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy ...

Genzyme will have significant rights to Alnylam’s portfolio of clinical and pre-clinical stage drug candidates. Alnylam will retain most product rights in North America and Western Europe, and will ...

, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that its multiple sclerosis pipeline, which includes a new generation of investigational treatments in early development, will be ...